AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+36.7%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$4.37B
AUM Growth
+$4.37B
(+44%)
Cap. Flow
+$620M
Cap. Flow
% of AUM
14.19%
Top 10 Holdings %
Top 10 Hldgs %
43.92%
Holding
157
New
22
Increased
25
Reduced
24
Closed
21
Top Buys
| 1 |
Seer Inc
SEER
|
$328M |
| 2 |
SQZ
SQZ Biotechnologies Company
SQZ
|
$46.6M |
| 3 |
Zillow
Z
|
$45.4M |
| 4 |
IGMS
IGM Biosciences
IGMS
|
$45.1M |
| 5 |
Praxis Precision Medicines
PRAX
|
$41.3M |
Top Sells
| 1 |
BioNTech
BNTX
|
$59.6M |
| 2 |
Alibaba
BABA
|
$52.4M |
| 3 |
Moderna
MRNA
|
$26.1M |
| 4 |
StoneCo
STNE
|
$21.2M |
| 5 |
Scholar Rock
SRRK
|
$19.2M |
Sector Composition
| 1 | Healthcare | 82.45% |
| 2 | Consumer Discretionary | 9.72% |
| 3 | Technology | 2.14% |
| 4 | Communication Services | 1.97% |
| 5 | Real Estate | 1.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPTX
26
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $42.6M | 0.92% | 350,000 +25,000 | +8% | +$3.05M |
|
|
27
Praxis Precision Medicines
PRAX
$958M
| $41.3M | 0.89% | +750,000 | New | +$41.3M |
|
|
CCXI
28
DELISTED
ChemoCentryx, Inc.
CCXI
| $40.2M | 0.86% | +650,000 | New | +$40.2M |
|
|
KRON
29
DELISTED
Kronos Bio
KRON
| $39.4M | 0.85% | +1,317,954 | New | +$39.4M |
|
|
CERE
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $37.8M | 0.81% | +2,282,100 | New | +$37.8M |
|
31
iTeos Therapeutics
ITOS
| $37M | 0.79% | 1,094,047 | – | – |
|
32
Foghorn Therapeutics
FHTX
$286M
| $34.9M | 0.75% | +1,720,720 | New | +$34.9M |
|
|
SAGE
33
DELISTED
Sage Therapeutics
SAGE
| $34.6M | 0.74% | 400,000 +177,700 | +80% | +$15.4M |
|
|
IMAB
34
I-MAB
IMAB
$340M
| $34.2M | 0.73% | 725,000 | – | – |
|
35
Denali Therapeutics
DNLI
$2.23B
| $33.5M | 0.72% | 400,000 | – | – |
|
|
SWTX
36
DELISTED
SpringWorks Therapeutics
SWTX
| $32.6M | 0.7% | 450,000 +165,000 | +58% | +$12M |
|
37
Mersana Therapeutics
MRSN
$36.5M
| $31.9M | 0.69% | 1,200,000 +200,000 | +20% | +$5.32M |
|
|
TRIL
38
DELISTED
Trillium Therapeutics Inc.
TRIL
| $30.9M | 0.66% | 2,100,000 +600,000 | +40% | +$8.83M |
|
|
RUBY
39
DELISTED
Rubius Therapeutics, Inc
RUBY
| $28.7M | 0.62% | 3,778,913 | – | – |
|
|
DCPH
40
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $28.5M | 0.61% | 500,000 -100,000 | -17% | -$5.71M |
|
41
Taysha Gene Therapies
TSHA
$797M
| $27.6M | 0.59% | 1,040,882 -100,000 | -9% | -$2.65M |
|
42
Adverum Biotechnologies
ADVM
$64.6M
| $27.1M | 0.58% | 2,500,000 +700,000 | +39% | +$7.59M |
|
43
Replimune Group
REPL
$422M
| $26.7M | 0.57% | 700,000 | – | – |
|
|
ALBO
44
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $26.3M | 0.56% | 700,000 -151,405 | -18% | -$5.68M |
|
45
ALX Oncology
ALXO
$62.7M
| $25.9M | 0.56% | 300,000 +200,000 | +200% | +$17.2M |
|
46
uniQure
QURE
$896M
| $25.3M | 0.54% | 700,000 -50,000 | -7% | -$1.81M |
|
47
NovaGold Resources
NG
$2.78B
| $25.1M | 0.54% | 2,600,000 | – | – |
|
48
Gossamer Bio
GOSS
$562M
| $22.8M | 0.49% | 2,358,968 | – | – |
|
|
TBIO
49
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $22.1M | 0.47% | 1,200,000 -200,000 | -14% | -$3.69M |
|
|
AGEN
50
Agenus
AGEN
$133M
| $21.9M | 0.47% | 6,900,000 | – | – |
|